Search results
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
Zacks via Yahoo Finance· 5 hours agoThe review is now expected to be completed by the end of this month. The FDA has, however, not...
Moderna's RSV Vaccine Approval Faces Setback as FDA Delays Decision
Homenewshere.com· 3 days agoModerna announced that the FDA had delayed approval of its RSV vaccine to the end of May due to...
Moderna: FDA Extends RSV Vaccine Review, But No Issues Flagged
Morningstar· 3 days agoThe company said the FDA cited administrative constraints for the delay, and that the agency is working to complete its review of mRNA-1345 by the end of the month. Moderna
AstraZeneca pulls Covid vaccine after admitting rare side effect
Daily Express· 6 days agoThe Oxford-AstraZeneca Covid vaccine is set to be withdrawn after the pharmaceutical giant admitted...
Novavax stock jumps 50% as Sanofi deal kicks off turning point for struggling vaccine maker
CNBC· 3 hours agoA vial labelled "Novavax V COVID-19 Vaccine" is seen in this illustration taken January 16, 2022....
Novavax (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal
Zacks via Yahoo Finance· 4 hours agoNovavax (NVAX) partners with Sanofi to market its COVID-19 vaccine and also develop novel...
Moderna Announces Update on Investigational RSV Vaccine
Morningstar· 3 days agoThe FDA has informed Moderna that it is working to conclude...
Moderna’s First Vaccine Was a Big Hit. Its Second Is a Let Down
Bloomberg via Yahoo Finance· 4 days ago(Bloomberg) -- Moderna Inc.’s pioneering Covid shot turned the company into a nearly $200 billion...
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
Motley Fool via Yahoo Finance· 8 hours agoFortunately, there are good reasons to believe the company has what it takes. Moderna is inching...
Unveiling Moderna (MRNA)'s Value: Is It Really Priced Right? A C
Guru Focus· 5 hours agoThis analysis aims to determine whether Moderna's stock is significantly overvalued by examining its current market performance and intrinsic value. Founded in 2010 and going ...